Posted by Michael Wonder on 12 Nov 2025
AstraZeneca’s Imfinzi, Imjudo, and Ultomiris clear reimbursement panel review
7 November 2025 - AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab), the anti-CTLA-4 immune checkpoint inhibitor Imjudo (tremelimumab), and the C5 complement inhibitor Ultomiris (ravulizumab) were reviewed by HIRA’s Pharmaceutical Reimbursement Evaluation Committee (PREC).
All three medicines passed the review.
